CLINICAL TRIALS PROFILE FOR LIRAGLUTIDE
✉ Email this page to a colleague
All Clinical Trials for liraglutide
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00154401 ↗ | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 2 | 2005-01-01 | This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group. |
| NCT00154414 ↗ | Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 2 | 2005-01-01 | This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group. |
| NCT00294723 ↗ | To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c | Terminated | Novo Nordisk A/S | Phase 3 | 2006-02-01 | This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years). |
| NCT00318422 ↗ | Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes | Completed | Novo Nordisk A/S | Phase 3 | 2006-05-01 | This trial is conducted globally (the United States of America excepted). This trial is designed to show the effect of treatment with liraglutide when added to existing glimepiride therapy and to compare this to both glimepiride monotherapy and to rosiglitazone as add-on therapy to glimepiride. |
| NCT00318461 ↗ | To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together | Completed | Novo Nordisk A/S | Phase 3 | 2006-05-01 | This trial is conducted in Europe, Oceania, Africa, Asia and South America. This trial is designed to show the effect of treatment with liraglutide when adding to existing metformin therapy and to compare it with the effects of metformin monotherapy and combination therapy of metformin and glimepiride. Two trial periods: A 6 month (26 weeks) randomised, double-blinded period followed by an 18 months open-label extension, in total 2 years (104 weeks). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for liraglutide
Condition Name
Clinical Trial Locations for liraglutide
Trials by Country
Clinical Trial Progress for liraglutide
Clinical Trial Phase
Clinical Trial Sponsors for liraglutide
Sponsor Name
